Failure to Implement Non-Pharmacological Interventions Before Ordering Antipsychotic for Insomnia
Summary
The deficiency involves the facility’s failure to ensure a resident’s drug regimen was free from unnecessary drugs by not developing and implementing non-pharmacological interventions prior to ordering an antipsychotic medication for insomnia. The resident had diagnoses including PTSD, bipolar disorder, anxiety disorder, and depression, and was cognitively intact on both admission and significant change MDS assessments. These assessments documented that the resident reported trouble falling or staying asleep for 7–11 days in the look-back periods, frequent moderate pain that occasionally affected sleep, and receipt of multiple medications including antidepressants, opioids, and other high-risk drugs. The care plan for insomnia, initiated shortly after admission, listed only general interventions such as administering medications per order and monitoring for causes of insomnia like medications, caffeine, overstimulation, depression, and anxiety, without individualized identification of the resident’s insomnia symptoms related to bipolar disorder or specific non-pharmacological strategies. The resident’s medication regimen included amitriptyline and trazodone for depression and insomnia, and quetiapine, an antipsychotic, ordered as needed for insomnia. Hospital discharge orders on one occasion included quetiapine 25 mg at bedtime daily for insomnia, and on readmission the NP continued quetiapine 25 mg every 24 hours PRN for insomnia for 14 days, in addition to trazodone 50 mg at bedtime for insomnia. The clinical record did not document behaviors related to bipolar disorder that would support antipsychotic use, nor did it show that non-pharmacological interventions were attempted or implemented before adding or continuing quetiapine for insomnia. The care plan for mood fluctuation focused on administering medications and monitoring for side effects and signs of mania or hypomania, but did not address specific behavioral or environmental approaches to manage insomnia. Staff interviews further showed a lack of documented insomnia or behavioral issues that would justify the PRN antipsychotic for sleep. Nursing and QMA staff reported they had not observed the resident having difficulty sleeping or significant behaviors; one LPN described the resident as becoming antsy when medications or call light responses were not immediate, but also noted the resident calmed with listening and conversation. Another CNA reported that prior to a hospital stay the resident occasionally had difficulty sleeping and woke up angry, but since returning had no sleep problems. The medication administration records for the relevant months showed the resident did not receive any doses of the PRN quetiapine. Despite this, the NP and DON discussed and chose to keep the quetiapine order in place after hospital discharge because it had been used in the hospital for insomnia, even though the FDA-approved indications for quetiapine do not include insomnia and the facility’s psychotropic medication policy requires that such drugs only be used when necessary to treat a specific or suspected condition per current standards of practice.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release June 24, 2026) and official state health department websites — never guesswork.
Trusted by long-term care providers and associations.



